Kempf Tibor, Wollert Kai C
Hannover Medical School, Hannover, Germany.
Heart Fail Clin. 2009 Oct;5(4):537-47. doi: 10.1016/j.hfc.2009.04.006.
The stress-responsive transforming growth factor-beta-related cytokine, growth-differentiation factor-15 (GDF-15), is emerging as a new biomarker in patients with cardiovascular disease. The circulating levels of GDF-15 are elevated and independently related to an adverse prognosis in acute coronary syndrome and left- or right-sided heart failure. GDF-15 adds significant prognostic information to established clinical and biochemical risk markers in these conditions. Elevated levels of GDF-15 may identify patients who have non-ST-elevation acute coronary syndrome who derive the greatest benefit from an invasive treatment strategy. As with other heart failure biomarkers, including BNP, it is currently not known what specific therapies could be used to reduce the risk associated with elevated levels of GDF-15 in heart failure. Further elucidation of the pathobiology and upstream inducers of this new biomarker may lead to new therapeutic concepts that address the risk associated with elevated GDF-15 levels. A commercial assay for GDF-15 should be available in the near future.
应激反应性转化生长因子-β相关细胞因子——生长分化因子15（GDF-15），正逐渐成为心血管疾病患者的一种新型生物标志物。GDF-15的循环水平升高，且与急性冠状动脉综合征及左心或右心衰竭的不良预后独立相关。在这些情况下，GDF-15为既定的临床和生化风险标志物增添了重要的预后信息。GDF-15水平升高可能有助于识别出从侵入性治疗策略中获益最大的非ST段抬高型急性冠状动脉综合征患者。与包括脑钠肽（BNP）在内的其他心力衰竭生物标志物一样，目前尚不清楚可用哪些具体疗法来降低心力衰竭中与GDF-15水平升高相关的风险。进一步阐明这种新型生物标志物的病理生物学及上游诱导因素，可能会带来针对GDF-15水平升高相关风险的新治疗理念。一种用于检测GDF-15的商业检测方法在不久的将来应该会问世。
